Stuka Paul bought 307,693 shares of InspireMD, Inc. at $0.65 for $200k on Nov 13, 2026

Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
Director
DIR
Filed Nov 17, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$200,000.45Shares × reported price
Shares traded
307,693Common Stock
Price per share
$0.65Reported price. Read footnotes for ranges.
% of reported position traded
72.62%This security and ownership context
Holdings after
731,397Indirect · See Footnote
Trade date
Nov 13, 2026Buy
Filed
Nov 17, 2026, 4:05 PM ET4-day reporting delay
Accession
0001493152-26-052827Code P · Transaction 403030
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 423,704 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 13, 2026Buy230,769$0.00$0Trade 403031
2 transaction rows in this filing. Joint filers share the same rows.

NSPR price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
NSPR · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 24, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +2.2%1w ago 0%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: Represents shares of common stock purchased by the Reporting Person through Osiris Investment Partners, L.P. ("Osiris") in the Issuer's underwritten public offering at a combined public offering price of $0.65 per share of common stock and accompanying Series L common stock warrants. F2: These securities are held by Osiris. The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. F3: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. F4: The Series L common stock warrants are immediately exercisable at an exercise price of $0.65 per share and expire on November 16, 2027.